Alere Inc.Tel: +1 (781) 647 3900Jon Russell, Vice President, FinanceDoug Guarino, Spokesman, Press OfficeJefferies International Limited Tel: +44 (0)20 7029 8000(Financial Adviser & Corporate Broker)Ian Crosbie Tariq HussainJulian Smith (Corporate Broking)Citigate Dewe RogersonTel: +44 (0)20 7282 2945(Public Relations Adviser)Ginny PulbrookJos Bieneman Sources and BasesUnless otherwise stated in this Announcement:
i) information relating to Axis-Shield has been extracted or derived, without material adjustment, from public sources;
ii) all prices quoted for Axis-Shield Shares have been derived from SEDOL and represent the closing middle market prices of Axis-Shield Shares on the relevant dates;
iii) references to a percentage of Axis-Shield Shares are based on the number of Axis-Shield Shares in issue (as sourced from the Regulatory Information Service announcement released by Axis-Shield on 15 July 2011);
iv) the Offer Price premium calculations have been calculated by reference to the Closing Price of 335 pence per Axis-Shield Share on 5 July 2011, being the last Business Day prior to the commencement of the Offer Period;
v) figures stated are subject to rounding approximations;
vi) the three month weighted average share price is calculated using both share price and volume data from Bloomberg from 5 April 2011 to 5 July 2011; and
vii) Axis Shield's key industry peers being referred to for the indices statement include Abaxis Inc, Alere Inc, BioMerieux S.A., Bio-Rad Laboratories Inc, DiaSorin S.p.A, Immucor Inc, Immunodiagnostic Systems Holdings plc, IRIS International Inc, Meridian Bioscience Inc and Quidel Corp. Share prices have been recorded for the period from 6 July 2011 to 23 September 2011 and sourced from Bloomberg.
Further InformationThe Alere Directors and Alere AS Holdings Directors accept responsibility for t
|SOURCE Alere Inc.|
Copyright©2010 PR Newswire.
All rights reserved